Home / Industry News / New Long-Term TEGSEDI Safety and Efficacy Data Featured as an Oral Presentation at 2019 American Academy of Neurology Annual Meeting (AAN)


NEURO-TTR phase 3 open-label extension study showed TEGSEDI® (inotersen) treatment continued to slow progression over two-year period in patients with Hereditary ATTR amyloidosis with polyneuropathy.

Greater efficacy and clinical benefit observed with early initiation of TEGSEDI and no new safety signals with longer duration of treatment.

For more information, click here


Share This